Covalent conjugation of Toll-like receptor ligands (TLR-L) to synthetic antigenic peptides
strongly improves antigen presentation in vitro and T lymphocyte priming in vivo. These
molecularly well defined TLR-L-peptide conjugates, constitute an attractive vaccination
modality, sharing the peptide antigen and a defined adjuvant in one single molecule. We
have analyzed the intracellular trafficking and processing of two TLR-L conjugates in
dendritic cells (DCs). Long synthetic peptides containing an ovalbumin cytotoxic T-cell …